Education
About Us
Working with TipRanks
Follow Us
Natera (NTRA)
NASDAQ:NTRA
Earnings Data
Report Date
May 07, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.63Last Year’s EPS
-0.56Same Quarter Last Year
Strong Buy
Based on 16 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 27, 2025
|% Change Since: -5.55%
|Next Earnings Date:May 07, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted strong financial performance, significant advancements in product coverage, and successful data initiatives. While there are some challenges, particularly in the immediate financial impact of new legislative measures and product introductions, the overall outlook remains positive with substantial growth opportunities in oncology and women's health.Company Guidance
During the 2024 Fourth Quarter Financial Results Conference Call, Natera provided extensive guidance on its future outlook. The company reported Q4 revenues of $476 million, marking a 53% year-on-year increase, with volumes up 26%. Gross margins significantly improved to 63% compared to 51% the previous year. The company generated approximately $46 million in cash flow in Q4, contributing to a total of $86 million for the year. For 2025, Natera projects revenues between $1.87 billion and $1.95 billion, with a focus on maintaining stable ASPs and achieving gross margin improvements above the 59% posted in Q4, excluding true-ups. The company's robust R&D efforts, expected to continue growing, are primarily directed at its MRD product line and early cancer detection initiatives. Natera also highlighted the recent Medicare coverage expansion for its Signatera test in non-small cell lung cancer, and aspired to capitalize on increasing reimbursement for women's health and organ health services.Record Revenue Growth
Natera reported Q4 revenues of $476 million, up 53% year-on-year, exceeding the pre-announcement figure by $4 million.
Significant Volume Increase
Volumes rose by 26% compared to Q4 of the previous year, with notable growth in the Signatera unit.
Improved Gross Margins
Gross margins increased to 63% in Q4 from 51% a year ago, reflecting improvements in COGS and pricing.
Positive Cash Flow
Natera generated $46 million in cash flow in Q4, contributing to a total of $86 million for the full year.
Expansion in Oncology Coverage
Medicare coverage expanded for Signatera in non-small cell lung cancer, stages 1-3, enhancing access for patients.
Advancements in Organ Health
Progress in organ health with upcoming studies like PEDAL and DEFINE expected to impact kidney and heart transplant monitoring.
Data-Driven Achievements
Signed over $10 million in data-related contracts in early 2025, showcasing momentum in leveraging clinical and genomic data.
---
NTRA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
NTRA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 27, 2025 | $156.61 | $155.59 | -0.65% |
| Nov 12, 2024 | $135.12 | $160.97 | +19.13% |
| Aug 08, 2024 | $107.70 | $114.57 | +6.38% |
| May 09, 2024 | $95.55 | $105.29 | +10.19% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Natera (NTRA) report earnings?
Natera (NTRA) is schdueled to report earning on May 07, 2025, TBA Not Confirmed.
What is Natera (NTRA) earnings time?
Natera (NTRA) earnings time is at May 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is NTRA EPS forecast?
NTRA EPS forecast for the fiscal quarter 2025 (Q1) is -0.63.
---